StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Complera / Eviplera (FTC / rilpivirine / TDF by Quarter

Complera / Eviplera (FTC / rilpivirine / TDF — legacy breakout) — Europe sales ($M) ($M)

QuarterlyAnnual

Gilead Sciences Complera / Eviplera (FTC / rilpivirine / TDF: $15M in Q4 2023, down 59.5% from a year earlier. That is the lowest of the 29 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2023
15
Period ended Dec 31, 2023
Change on a year earlier
-59.5%
37 in Q4 2022
History
29 quarters
Since Q4 2016
Sources
21
Documents cited below

Where the Q4 2023 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2024-02-23) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedComplera / Eviplera (FTC / rilpivirine / TDF — legacy breakout) — Europe sales ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202315-59.5%Form 10-K (filed 2024-02-23) ↗
Q3 2023Sep 30, 202318-14.3%Form 10-Q (filed 2023-11-07) ↗
Q2 2023Jun 30, 202316-48.4%Form 10-Q (filed 2023-08-04) ↗
Q1 2023Mar 31, 202322-8.3%Form 10-Q (filed 2023-05-03) ↗
Q4 2022Dec 31, 202237-2.6%Form 10-K (filed 2024-02-23) ↗
Q3 2022Sep 30, 202221-32.3%Form 10-Q (filed 2023-11-07) ↗
Q2 2022Jun 30, 202231-20.5%Form 10-Q (filed 2023-08-04) ↗
Q1 2022Mar 31, 202224-29.4%Form 10-Q (filed 2023-05-03) ↗
Q4 2021Dec 31, 202138+8.6%Form 10-K (filed 2024-02-23) ↗
Q3 2021Sep 30, 202131-11.4%Form 10-Q (filed 2022-11-02) ↗
Q2 2021Jun 30, 202139-7.1%Form 10-Q (filed 2022-08-08) ↗
Q1 2021Mar 31, 202134-27.7%Form 10-Q (filed 2022-05-04) ↗
Q4 2020Dec 31, 2020350.0%Form 10-K (filed 2023-02-22) ↗
Q3 2020Sep 30, 202035-22.2%Form 10-Q (filed 2021-11-03) ↗
Q2 2020Jun 30, 202042-41.7%Form 10-Q (filed 2021-08-05) ↗
Q1 2020Mar 31, 202047-24.2%Form 10-Q (filed 2020-05-06) ↗

Cite this data

StockData. (2026). Gilead Sciences Complera / Eviplera (FTC / rilpivirine / TDF ($M), quarterly Q4 2016–Q4 2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv-complera-eu

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.